- Home
- ABTS vs ALZN Comparison
ABTS vs ALZN Comparison
Compare ABTS & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- ALZN
- Stock Information
- Founded
- ABTS 2010
- ALZN 2016
- Country
- ABTS Hong Kong
- ALZN United States
- Employees
- ABTS N/A
- ALZN N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- ABTS Technology
- ALZN Health Care
- Exchange
- ABTS Nasdaq
- ALZN Nasdaq
- Market Cap
- ABTS 8.9M
- ALZN 7.5M
- IPO Year
- ABTS N/A
- ALZN 2021
- Fundamental
- Price
- ABTS $7.79
- ALZN $2.36
- Analyst Decision
- ABTS
- ALZN Strong Buy
- Analyst Count
- ABTS 0
- ALZN 1
- Target Price
- ABTS N/A
- ALZN $42.00
- AVG Volume (30 Days)
- ABTS 79.8K
- ALZN 132.3K
- Earning Date
- ABTS 08-13-2025
- ALZN 12-11-2025
- Dividend Yield
- ABTS N/A
- ALZN N/A
- EPS Growth
- ABTS N/A
- ALZN N/A
- EPS
- ABTS N/A
- ALZN N/A
- Revenue
- ABTS $7,037,156.00
- ALZN N/A
- Revenue This Year
- ABTS N/A
- ALZN N/A
- Revenue Next Year
- ABTS N/A
- ALZN N/A
- P/E Ratio
- ABTS N/A
- ALZN N/A
- Revenue Growth
- ABTS 31.69
- ALZN N/A
- 52 Week Low
- ABTS $1.35
- ALZN $2.06
- 52 Week High
- ABTS $14.10
- ALZN $15.21
- Technical
- Relative Strength Index (RSI)
- ABTS 52.56
- ALZN 48.65
- Support Level
- ABTS $6.00
- ALZN $2.27
- Resistance Level
- ABTS $9.03
- ALZN $2.56
- Average True Range (ATR)
- ABTS 1.06
- ALZN 0.17
- MACD
- ABTS -0.08
- ALZN 0.01
- Stochastic Oscillator
- ABTS 50.13
- ALZN 52.62
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.